GSK
1 year ago ⋅ English ⋅ 3 min read
Newsroom
GSK enters exclusive license agreement with Hansoh for HS-20093

For media and investors only- Hansoh’s HS-20093 builds on GSK’s oncology portfolio of clinical-stage antibody-drug conjugates, following earlier agreement for Hansoh’s... Read More
GSK
1 year ago ⋅ English ⋅ 6 min read
Newsroom
Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial

For media and investors only- Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib improved progression-free survival vs. chemotherapy alone in both the overall and mism... Read More
GSK
1 year ago ⋅ English ⋅ 4 min read
Newsroom
Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk

For media and investors onlyJapan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at incre... Read More
GSK
1 year ago ⋅ English ⋅ 6 min read
Newsroom
GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer

For media and investors only- European Commission also converts previous conditional approval for Jemperli to full approval as a monotherapy for second-line dMMR/MSI-H recurrent or adva... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions

For media and investors only- New IQVIA Institute for Human Data Science report, funded by GSK, explores the role of social and structural determinants of health to identify enablers an... Read More
GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence

For media and investors only- A new GSK survey shows a large number of adults do not understand how shingles may be triggered 1- More than half of adults surveyed incorrectly believe th... Read More